ArticleThe Lancet. Infectious diseases2019
The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study.
Article in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 129 citations in OpenAlex.
- Pre-exposure prophylaxis as a complementary vaccination strategy to reduce rabies in Kerala, India: a cost-effectiveness modelling study.The Lancet regional health. Southeast Asia · 2026Article
- Article
- Economic Impact of Malignant Catarrhal Fever on Cattle Production in Lephalale Municipality, Limpopo Province, South Africa.Veterinary sciences · 2026Article
- Translating one health research evidence into action: co-production of rabies control knowledge in Côte d'Ivoire.Health research policy and systems · 2026Article
- Comparative effectiveness and cost-effectiveness of policies for provisioning rabies post-exposure vaccines.Vaccine · 2026Article
- Experiences of piloting integrated bite case management in Zaria Metropolis, Nigeria.Frontiers in tropical diseases · 2026Article
- Rabies post-exposure prophylaxis in children: adherence to national guidelines in a country at ongoing risk.BMC public health · 2026Article
- Working towards a single-dose vaccine for rabies post-exposure prophylaxis.Future virology · 2026Article
- Healthcare accessibility to rabies post-exposure prophylaxis in rural Kenya: implications for vaccine placement and travel time.Frontiers in microbiology · 2026Article
- Practitioner's perspectives on access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practice.PLOS global public health · 2026Article
- Rabies Post Exposure Vaccine Effectiveness: A Retrospective Case-Control Study in Amhara Region, Ethiopia.Scientifica · 2026Article
- Drivers of rabies post-exposure prophylaxis noncompletion in Cambodia, 2019 to 2022.PLoS neglected tropical diseases · 2025Article
- Access to Rabies Post-Exposure Prophylaxis in Tanzania: A mixed-methods and theoretically-informed study to inform policy and practise.medRxiv : the preprint server for health sciences · 2025Article
- Disparities in Global Rabies Burden from GBD 2021: Children, older adults, and low-SDI countries at continued risk.PLoS neglected tropical diseases · 2025Article
- Rabies elimination in the WHO African Region.Bulletin of the World Health Organization · 2025Article
- The Economic Landscape of Global Rabies: A Scoping Review and Future Directions.Tropical medicine and infectious disease · 2025Review
- Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations.Cell host & microbe · 2025Article
- Article
- Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.Vaccine · 2025Article
- Knowledge and practices on dog bite management for rabies prevention in eThekwini, South Africa.Journal of public health in Africa · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author at 18 institutions in 13 countries.
Funding
Abstract
backgroundTens of thousands of people die from dog-mediated rabies annually. Deaths can be prevented through post-exposure prophylaxis for people who have been bitten, and the disease eliminated through dog vaccination. Current post-exposure prophylaxis use saves many lives, but availability remains poor in many rabies-endemic countries due to high costs, poor access, and supply.
methodsWe developed epidemiological and economic models to investigate the effect of an investment in post-exposure prophylaxis by Gavi, the Vaccine Alliance. We modelled post-exposure prophylaxis use according to the status quo, with improved access using WHO-recommended intradermal vaccination, with and without rabies immunoglobulin, and with and without dog vaccination. We took the health provider perspective, including only direct costs.
findingsWe predict more than 1 million deaths will occur in the 67 rabies-endemic countries considered from 2020 to 2035, under the status quo. Current post-exposure prophylaxis use prevents approximately 56 000 deaths annually. Expanded access to, and free provision of, post-exposure prophylaxis would prevent an additional 489 000 deaths between 2020 and 2035. Under this switch to efficient intradermal post-exposure prophylaxis regimens, total projected vaccine needs remain similar (about 73 million vials) yet 17·4 million more people are vaccinated, making this an extremely cost-effective method, with costs of US$635 per death averted and $33 per disability-adjusted life-years averted. Scaling up dog vaccination programmes could eliminate dog-mediated rabies over this time period; improved post-exposure prophylaxis access remains cost-effective under this scenario, especially in combination with patient risk assessments to reduce unnecessary post-exposure prophylaxis use.
interpretationInvesting in post-exposure vaccines would be an extremely cost-effective intervention that could substantially reduce disease burden and catalyse dog vaccination efforts to eliminate dog-mediated rabies.
fundingWorld Health Organization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.